MediMab Biotherapeutics is a ground-breaking biotherapeutic company focused on the generation of novel immunotherapies for the treatment of cancer. Our discovery platform uses advances in systems biology combined with sophisticated immunological solutions to identify and significantly improve first-in-class immuno-oncology drugs. We are actively targeting a range of advanced and solid tumours.
MediMab Biotherapeutics is a Korean start up divided between Seoul, Korea, and Oxford, UK. The Oxford team is focused on cutting-edge immunological solutions and identifying lead candidate therapies for the next stage of development.
The Innovation Building
The Old Road Campus
Website: MediMab Biotherapeutics Ltd.